Preclinical Evaluation Module

• Preclinical Evaluation Module is a systematic framework that combines standardized MRI data acquisition with automated processing to assess disease models and therapeutic interventions.
• It employs a multi-stage processing pipeline—including denoising, parameter mapping, and deep learning brain extraction—to ensure reproducibility and harmonization across multicenter studies.
• Quantitative endpoints such as infarct volume, hemispheric atrophy, and midline shift are mathematically defined and rigorously validated against manual tracings and histology.

A Preclinical Evaluation Module is a structured computational or experimental workflow designed to objectively assess disease models, therapeutic interventions, or acquisition/analysis techniques prior to clinical translation. It systematically encompasses standardized data acquisition, rigorous processing pipelines, quantitative metrics, and validated endpoints to ensure robustness, scalability, and reproducibility across preclinical multicenter studies. Such modules are integral in screening candidate therapies, benchmarking device performance, or harmonizing data workflows in preclinical research networks, as exemplified by the Stroke Preclinical Assessment Network (SPAN) MRI pipeline (Cabeen et al., 2022).

1. Standardized Preclinical MRI Data Acquisition

Preclinical evaluation modules implement stringent acquisition protocols to mitigate inter-site and longitudinal variability in multicenter animal model studies. The SPAN framework adopts the following elements:

• Animal model: mouse middle cerebral artery occlusion (MCAO) as the ischemic injury paradigm.
• Scanning infrastructure: six sites using Bruker 7T, 9.4T, or 11.7T MRI scanners (five volume coils, one surface coil).
• Time points: acute (Day 2) for lesion quantification and chronic (Day 30) for atrophy.
• Imaging modalities and parameters:
  • Multi-echo T2-weighted MRI (TE=15,30,45 ms; 10-echo variants TE=10–100 ms).
  • Diffusion-weighted imaging (b-values 0,500,1000 s/mm²).
  • All images resampled to 150 µm isotropic voxels.
• Data logistics: DICOM files transferred and archived in a centralized LONI Image Database, automated conversion to NIfTI.
• Cohort size: pilot, main, and follow-up batches totaling 1,368 MRI sessions, reflecting real preclinical study scales.

This design enables harmonization of spatial resolution, temporal endpoints, and data, which is critical for downstream reproducibility and scalability.

2. Fully Automated, Multi-Stage Processing Pipeline

The computational core consists of a modular set of algorithms operating in a sequential, reproducible pipeline:

• Preprocessing: DICOM parsing (dcm2nii), coordinate correction, adaptive non-local means denoising (Manjón's method), tricubic interpolation for isotropic resampling.
• Relaxometry and parameter map derivation: multi-echo T2 fitting (yielding R2 = 1/T2), DWI-based apparent diffusion coefficient (ADC) mapping.
• Quality control: Otsu thresholding for foreground segmentation; SNR, CNR, variance-to-noise ratio computed per scan.
• Automated brain extraction: 2D U-Net CNN (PyTorch), leveraging four-channel (R2+ADC) inputs across all three anatomical planes; trained on 180 semi-automated masks, with rigorous data augmentation.
• Spatial normalization and harmonization: linear registration of R2 maps with the MBAT template; site harmonization via intensity histogram mode-scaling.
• Lesion and CSF segmentation: thresholding (R2 soft-inverted sigmoid at 0.8, ADC at 1.5), refinement by median filtering, hysteresis, atlas-based hemisphere restriction; CSF defined as R2>0.75 and ADC>1.25.
• Midline shift and hemispheric volumetry: ventricular centroiding, quadratic midline fitting, per-hemisphere volumetrics via registered atlas masks.
• Reporting and visualization: automated output of lesion/brain/CSF volumes, atrophy, midline shift, and QC metrics; generation of 3D lesion probability surfaces and batch reporting in R.

This architecture enables high-throughput, site-agnostic performance with minimal manual intervention.

3. Quantitative Endpoints and Mathematical Definitions

Critical quantitative endpoints are precisely operationalized:

• Infarct volume: $V_{\text{infarct}} = \sum_{i\in L} v_i$, with v_i the isotropic physical voxel volume and L the lesion voxel set post-segmentation.
• Hemispheric atrophy (Day 30): $\Delta V = V_{\text{contra}} - V_{\text{ipsi}}$, sensitive to chronic tissue loss.
• Midline shift: $d = |x_{\text{estimated}} - x_{\text{atlas}}|$, normalized as $d_{\text{norm}} = d/W_{\text{brain}}$.
• Quality control metrics:
  • $$\mathrm{SNR} = \mu_{\text{signal}}/\sigma_{\text{background}}$$
  • $$\mathrm{CNR} = (\mu_{\text{lesion}} - \mu_{\text{normal}})/\sigma_{\text{noise}}$$
  • $$\mathrm{VNR} = \sigma_{\text{signal}}/\sigma_{\text{background}}$$
• Additional endpoints: motion artifact scoring, atrophy indices per time point, lateralization index for hemisphere comparison.

These definitions are consistently applied and are directly reproducible.

4. Validation Against Manual and Histology Gold Standards

Module reliability is established by direct comparison to both expert manual segmentations and independent tissue histology:

• Manual tracing comparison: For ten acute-phase (Day 2) scans, the automated module’s mean lesion volume (11.38 mm³) matched the blinded expert consensus (11.56 mm³), with human–auto RMSE 2.99 mm³ versus human–human RMSE 2.22 mm³; Pearson correlation r=0.957.
• Histological validation: 37-mouse subset analyzed for TTC-stained lesion areas (746 slices, annotated by six raters); MRI–TTC volume correlation r=0.743 (full), r=0.865 (high-reliability subset, CoV<5%), confirming validity of image-based quantification.
• Site effect analysis: Inclusion of site as a covariate in statistical models is justified by pronounced site dependence of total brain volume (F_{5,1347}=264.4, p<10⁻¹⁵), ensuring robust multicenter harmonization.

This extensive validation structure ensures that observed module outputs are quantitatively precise and generalizable.

5. Deployment, Scalability, and Workflow Automation

The SPAN evaluation module achieves scalability and operational efficiency via several mechanisms:

• Batch throughput: Average processing time per scan is ~1 h 48 min; 1,368 cases processed using a 4,096-core grid, achieving 98.5% completion and >1,300 analyzable sessions.
• Automation: Shell, Python, QIT, ANTs, PyTorch, and R scripts orchestrated for end-to-end automation, triggered upon new data ingestion.
• Quality assurance: Automated per-case and cohort-level reporting with visualization for coordinating statisticians; batch-mode troubleshooting of failures (only ~4% pipeline failure, typically not at brain extraction stage).
• Reproducibility: Open-source code repository (https://github.com/cabeen/span-mri), explicit parameter documentation for transparent module adoption and adaptation across studies.

The pipeline provides a robust, reproducible platform for scalable multisite preclinical stroke studies, with potential for direct generalization to other organ systems and disease models.

6. Generalization to Other Preclinical Imaging and Evaluation Contexts

The design principles of the SPAN module—comprehensive acquisition standardization, modular and automated processing, mathematically explicit endpoints, rigorous multicenter validation, extensive automation, and reproducibility—can be adapted to broader preclinical evaluation modules. Adjacent modules (brain extraction, diffusion MRI, PET, MRSI) mirror similar structures: open-source algorithm stacks, rigorous endpoint definitions, and embedding of automation and batch scalability (Tarakci et al., 2022, Jelescu et al., 2022, Schug et al., 2015, Nossa et al., 12 Dec 2025). Incorporating these approaches enhances the methodological rigor and translational reliability of preclinical biomedical research.

---

References:

• Computational Image-based Stroke Assessment for Evaluation of Cerebroprotectants with Longitudinal and Multi-site Preclinical MRI (Cabeen et al., 2022)
• Evaluating U-net Brain Extraction for Multi-site and Longitudinal Preclinical Stroke Imaging (Tarakci et al., 2022)